Bupivacaine-epinephrine
Phase 3Small molecule
Bupivacaine-epinephrine is one of 36 small molecule programs targeting Agitation. It is currently in Phase 3.
5
Indications
14
Total Trials
3
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Bariatric Surgery
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Adipex-P
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Topamax
WWim Janssens
Approved
Cyklokapron
JJ Molner
Approved
IC-Green
PProvepharm SAS
Approved
Spravato
WWim Janssens
Approved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Glucophage
EMD SeronoPhase 3
Gas-X
PPortuguese Oncology Institute, Coimbra
Phase 3
Bupivacaine-epinephrine
UUniversity of Aarhus
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Post Operative Pain2 trials
Total Knee Arthroplasty2 trials
Thoracoscopic Lobectomy1 trial
7 more indications
Erector Spinae Plane Block1 trial
Erector Spinae Plane Block Versus Intercostal for VATS
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT03902782·100 enrolled
Shoulder pain1 trial
Intrapleural Bupivacaine for Ipsilateral Shoulder Pain After Thoracotomy
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT03862404·42 enrolled
Postoperative Pain Control1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bupivacaine-epinephrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Aarhus